Saptaz

Saptaz

Manufacturer:

Makcur Laboratories

Distributor:

Bell-Kenz Pharma

Marketer:

SRS Life Sciences
Concise Prescribing Info
Contents
Cefepime HCl 1 g, tazobactam Na 125 mg
Indications/Uses
Intra-abdominal infections, pneumonia, skin & skin structure infections, UTI. Empiric therapy in febrile neutropenic patients.
Dosage/Direction for Use
IV/IM Adult Intra-abdominal infections 2 g IV every 12 hr for 7-10 days. Moderate to severe pneumonia caused by Strep pneumonia (including those w/ concurrent bacteremia) 1-2 g IV every 12 hr for 10 days. Hospital-acquired, ventilator-associated or healthcare-associated pneumonia Initially 1-2 g every 8-12 hr. Moderate to severe uncomplicated skin & skin structure infections caused by Staph aureus or Strep pyogenes 2 g IV every 12 hr for 10 days. Mild to moderate uncomplicated or complicated UTI (including those associated w/ pyelonephritis &/or w/ concurrent bacteremia) 500 mg-1 g IV/IM every 12 hr for 7-10 days. Severe uncomplicated or complicated UTI (including those associated w/ pyelonephritis &/or w/ concurrent bacteremia) 2 g IV every 12 hr for 10 days. Empiric therapy in febrile neutropenic patient 2 g IV every 8 hr for 7 days or until neutropenia resolves. Childn 2 mth-16 yr (weighing up to 40 kg) Uncomplicated & complicated UTI (including pyelonephritis) 50 mg/kg/dose every 12 hr. Uncomplicated skin & skin structure infections & pneumonia 50 mg/kg/dose every 12 hr. Febrile neutropenic patient 50 mg/kg/dose every 8 hr. Renal impairment Adult Infections Initial dose of 500 mg. Maintenance: CrCl 30-60 mL/min 500 mg every 24 hr, 11-29 mL/min 500 mg every 24 hr, <11 mL/min 250 mg every 24 hr. Initial dose of 1 g. Maintenance: CrCl 30-60 mL/min 1 g every 24 hr, 11-29 mL/min 500 mg every 24 hr, <11 mL/min 250 mg every 24 hr. Initial dose of 2 g. Maintenance: CrCl 30-60 mL/min 2 g every 24 hr, 11-29 mL/min 1 g every 24 hr, <11 mL/min 500 mg every 24 hr. Empiric therapy in febrile neutropenic patient Initial dose of 2 g. Maintenance: CrCl 30-60 mL/min 2 g every 12 hr, 11-29 mL/min 2 g every 24 hr, <11 mL/min 1 g every 24 hr. Hemodialysis Infections 1 g on 1st day of treatment followed by 500 mg every 24 hr. Empiric therapy in febrile neutropenic patients 1 g on 1st day followed by 1 g every 24 hr. Administer the same time each day at the completion of procedure on hemodialysis days. Patient undergoing CAPD Administer usual dose once every 48 hr.
Contraindications
Hypersensitivity to cefepime, tazobactam or other cephalosporins & penicillins.
Special Precautions
Previous hypersensitivity reactions to cephalosporins, penicillins or other drugs. CrCl ≤60 mL/min. Pregnancy & lactation.
Adverse Reactions
Local reactions including phlebitis, pain &/or inflammation; rash. +ve Coombs' test (w/o hemolysis); decreased P; increased ALT/SGPT, AST/SGOT, eosinophils; abnormal PTT, PT.
Drug Interactions
Cefepime: Increased potential of nephrotoxicity & ototoxicity w/ high doses of aminoglycosides. Nephrotoxicity may occur w/ potent diuretics eg, furosemide.
MIMS Class
Antibacterial Combinations
ATC Classification
J01DE51 - cefepime and beta-lactamase inhibitor ; Belongs to the class of fourth generation cephalosporins. Used in the systemic treatment of infections.
Presentation/Packing
Form
Saptaz powd for inj
Packing/Price
(+ 10 mL diluent amp) 20 mL x 1's (P1,500/box)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in